WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity-associated genes and alleles.
|
31075510 |
2019 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This study aimed to investigate relationships between times in therapeutic range (TTR) or warfarin sensitivity indexes (WSI) and VKORC1-1639G>A and CYP2C9 polymorphisms in patients with left ventricular assist devices (LVAD).
|
29781049 |
2018 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Decreased warfarin sensitivity (ie, weekly warfarin dose of >21 mg) was associated with increased height, increased weight, having diabetes mellitus, VKORC1 genotype GG, and CYP2C9 genotype 1/1.
|
25830869 |
2017 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
A multiplex allele-specific PCR reaction was used to generate products corresponding to 3 genetic variants associated with warfarin sensitivity [CYP2C9 *2, CYP2C9 *3, and VKORC1 (1173C>T)] and an internal control product.
|
27990512 |
2017 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population.
|
28408837 |
2017 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR).
|
27581200 |
2016 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The effects of genetic polymorphisms at the vitamin K epoxide reductase [VKORC1] and cytochrome P450 2C9 [CYP2C9] loci have been increasingly acknowledged as contributory factors of enhanced warfarin sensitivity.
|
22571356 |
2012 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
|
22071881 |
2012 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
In our study population, no significant correlation could be detected between CYP2C9*3, CYP2C9C-65 (rs9332127), CYP4F2 rs2108622, GGCX rs12714145, EPHX1 rs4653436 and PROC rs1799809 with warfarin sensitivity.
|
21639946 |
2011 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
* Although CYP2C9*2 and *3 are important genetic factors for the warfarin dose, one of the CYP2C9 SNPs, IVS-65G>C, has been suggested to be associated with warfarin sensitivity.
|
20653674 |
2010 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
To investigate the contribution of genetic polymorphisms of vitamin K epoxide reductase complex subunit 1 gene VKORC1-1639G>A, cytochrome P450 2C9 gene (CYP2C9), EPHXI, and clinical factors to warfarin sensitivity in southwest Chinese Han patients with mechanical heart valve prostheses.
|
20842355 |
2010 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The relationship between warfarin sensitivity and CYP2C9 and VKORC1 variants is strong, and is the basis for several proposed dosing algorithms.
|
20386359 |
2010 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
To establish individualized warfarin therapy, we investigated the contribution of genetic variations of vitamin K epoxide reductase complex subunit 1 gene (VKORC1) -1639 G>A and Cytochrome P450 2C9 gene (CYP2C9) and clinical factors on warfarin sensitivity in Japanese patients.
|
19135231 |
2009 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The allelic variants found to most affect warfarin sensitivity are CYP2C9*1*1-VKORC1BB (less warfarin sensitivity than typical); CYP2C9*1*1-VKORC1AA (considerable variance in INR throughout initiation); CYP2C9*1*2-VKORC1AB (more sensitivity to warfarin than typical); CYP2C9*1*3-VKORC1AB (much more sensitivity to warfarin than typical); CYP2C9*1*2-VKORC1AB (much more sensitivity to warfarin than typical); CYP2C9*1*3-VKORC1AA (much more sensitivity to warfarin than typical); and CYP2C9*2*2-VKORC1AB (much more sensitivity to warfarin than typical).
|
19955245 |
2009 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We screened a new polymorphism of CYP2C9 and investigated its role in warfarin sensitivity.
|
16413010 |
2006 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
However, the genetic polymorphism in exon 4 of CYP 2 C 9 may not be associated with the warfarin sensitivity in this patient population.
|
16133893 |
2005 |
WARFARIN SENSITIVITY (disorder)
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We determined DNA sequence variants in CYP2C9 and VKORC1 in 16 Chinese patients having warfarin sensitivity (< or = 1.5 mg/day, n = 11) or resistance (> or = 6.0 mg/day, n = 5), 104 randomly selected Chinese patients receiving warfarin, 95 normal Chinese controls and 92 normal Caucasians.
|
15888487 |
2005 |